Gallo Ruelas Mariano, Alvarado-Gamarra Giancarlo, Aramburu Adolfo, Dolores-Maldonado Gandy, Cueva Karen, Rojas-Limache Gabriela, Diaz-Parra Carmen Del Pilar, Lanata Claudio F
Humanify Centro de Bienestar Integral, Instituto de Investigación Nutricional - IIN, Lima, Peru.
Faculty of Science Health, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.
Eur J Nutr. 2024 Dec 21;64(1):51. doi: 10.1007/s00394-024-03564-y.
Bioavailability studies and observational evidence suggest that heme iron (HI) may have greater impact on iron status indicators compared with non-heme iron (NHI). This systematic review and meta-analysis aimed to review the current evidence on the effect of the administration of HI compared with NHI for improving iron status in non-hospitalized population groups.
We searched Pubmed, CENTRAL, Scopus, Web of Science, and LILACS from inception to July 2024. There was no language restriction or exclusion based on age or iron status. Only randomized controlled trials comparing HI with NHI were considered. A random-effects meta-analysis was performed to compare the effect of treatments for iron status indicators and total side effects (including gastrointestinal side effects). We measured the certainty of the evidence (CoE) using GRADE assessment.
After screening 3097 articles, 13 studies were included. Most of the interventions used HI in low doses combined with NHI. The meta-analysis showed higher hemoglobin increases in children with anemia or low iron stores receiving HI (MD 1.06 g/dL; 95% CI: 0.34; 1.78; CoE: very low). No statistically significant difference between interventions were found for any iron status indicator in the other population subgroups (CoE: very low). Participants receiving HI had a 38% relative risk reduction of total side effects compared to NHI (RR 0.62; 95% CI 0.40; 0.96; CoE: very low).
The current evidence comparing HI with NHI is very limited, preliminary findings suggest that interventions using HI may result in fewer side effects and may be superior in children with iron deficiency or anemia. However, given the very low certainty of the evidence, these results need further investigation through high-quality clinical trials.
CRD42023483157.
生物利用度研究及观察性证据表明,与非血红素铁(NHI)相比,血红素铁(HI)可能对铁状态指标有更大影响。本系统评价和荟萃分析旨在回顾当前关于HI与NHI给药对改善非住院人群铁状态影响的证据。
我们检索了从创刊至2024年7月的PubMed、CENTRAL、Scopus、Web of Science和LILACS。没有语言限制,也不基于年龄或铁状态进行排除。仅纳入比较HI与NHI的随机对照试验。进行随机效应荟萃分析以比较治疗对铁状态指标和总副作用(包括胃肠道副作用)的影响。我们使用GRADE评估来衡量证据的确定性(CoE)。
在筛选3097篇文章后,纳入了13项研究。大多数干预措施使用低剂量HI与NHI联合。荟萃分析显示,接受HI的贫血或铁储备低的儿童血红蛋白升高幅度更大(MD 1.06 g/dL;95%CI:0.34;1.78;CoE:极低)。在其他人群亚组中,任何铁状态指标的干预措施之间均未发现统计学上的显著差异(CoE:极低)。与NHI相比,接受HI的参与者总副作用的相对风险降低了38%(RR 0.62;95%CI 0.40;0.96;CoE:极低)。
目前比较HI与NHI的证据非常有限,初步研究结果表明,使用HI的干预措施可能副作用更少,并且在缺铁或贫血儿童中可能更具优势。然而,鉴于证据的确定性极低,这些结果需要通过高质量的临床试验进一步研究。
CRD42023483157。